Biotechnology Research Institute, Microbial Biotechnology Department
National Research Centre
Vaccination, Infectious diseases, Immunology, Cancer Research
Dominik Damm, Ehsan Suleiman, Jannik T. Wagner, Stephan Klessing, Felix Pfister, Hassan Elsayed, Bernd Walkenfort, Jule Stobrawe, Julia Mayer, Elisabeth Lehner,et al. Elsevier BV
Rehab I. Moustafa, Ahmed H.I. Faraag, Reem El-Shenawy, Mona M. Agwa, and Hassan Elsayed Elsevier BV
Mona M. Agwa, Heba Elmotasem, Hassan Elsayed, Abdallah S. Abdelsattar, Ahmed M. Omer, Doaa T. Gebreel, Mohamed S. Mohy-Eldin, and Moustafa M.G. Fouda Elsevier BV
Essam Kotb, Noureddine Ouerfelli, Naouel Zrelli, Khaoula Briki, Asmaa Ahmed, Mohammed Medhat, Hassan Elsayed, and Mohamed El-Kassas Egypts Presidential Specialized Council for Education and Scientific Research
M. Samer, E. M. Abdelsalam, S. Mohamed, H. Elsayed, and Y. Attia Springer Science and Business Media LLC
Mona M. Agwa, Marwa M. Abu-Serie, Doaa A. Abdelmonsif, Nermine Moussa, Hassan Elsayed, Sherine N. Khattab, and Sally Sabra Elsevier BV
Yasser A. Attia, Ashwaq M. Al Nazawi, Hassan Elsayed, and Mahmoud W. Sadik Elsevier BV
Mohamed El Kassas, Noha Asem, Amr Abdelazeem, Ahmad Madkour, Hamdy Sayed, Ahmed Tawheed, Ahmed Al Shafie, Mahmoud Gamal, Hassan Elsayed, Mohamed Badr,et al. Journal of Infection in Developing Countries
Introduction: The recently discovered novel coronavirus disease (COVID-19) has emerged in Wuhan, China, since January 2020. Egypt reported a low incidence of infection when compared with other countries. The aim of the study was to assess the characterization of COVID-19 infection among the Egyptian population.
Methodology: Data were collected from a single COVID-19 quarantine hospital in Cairo. A total number of 195 cases were included with their clinical, laboratory, and radiological data.
Results: Three different age groups behaved differently for COVD-19 infection. The pediatric age group was asymptomatic entirely, the middle age group (18-50 years) were asymptomatic in 53.3% of cases, while 77.9% of those above 50 years were symptomatic (p ≤ 0.001). The latter group had a high incidence of COVID-pneumonia in (83.1%), and moderate to critical presentations were encountered in 66.3% of them. Neutrophil to lymphocyte (N/L) ratio correlated directly with the age and case severity. C-reactive protein (CRP) and computed tomography scan chest (CT-chest) had added value on COVID-19 diagnosis in suspected cases.
Conclusions: In Egypt, patients above 50 years are at a higher risk for symptomatic COVID-19 infection and leaner for moderate to critical COVID-19 presentation. The triad of CT-chest, CRP, and N/L ratio could be an integrated panel for assessing disease severity.
Hassan Elsayed, Ghulam Nabi, William J. McKinstry, Keith K. Khoo, Johnson Mak, Andres M. Salazar, Matthias Tenbusch, Vladimir Temchura, and Klaus Überla American Society for Microbiology
ABSTRACT Induction of persistent antibody responses by vaccination is generally thought to depend on efficient help by T follicular helper cells. Since the T helper cell response to HIV Env may not be optimal, we explored the possibility of improving the HIV Env antibody response to virus-like particle (VLP) vaccines by recruiting T helper cells induced by commonly used licensed vaccines to provide help for Env-specific B cells. B cells specific for the surface protein of a VLP can internalize the entire VLP and thus present peptides derived from the surface and core proteins on their major histocompatibility complex class II (MHC-II) molecules. This allows T helper cells specific for the core protein to provide intrastructural help for B cells recognizing the surface protein. Consistently, priming mice with an adjuvanted Gag protein vaccine enhanced the HIV Env antibody response to subsequent booster immunizations with HIV VLPs. To harness T helper cells induced by the licensed Tetanolpur vaccines, HIV VLPs that contained T helper cell epitopes of tetanus toxoid were generated. Tetanol-immunized mice raised stronger antibody responses to immunizations with VLPs containing tetanus toxoid T helper cell epitopes but not to VLPs lacking these epitopes. Depending on the priming immunization, the IgG subtype response to HIV Env after the VLP immunization could also be modified. Thus, harnessing T helper cells induced by other vaccines appears to be a promising approach to improve the HIV Env antibody response to VLP vaccines. IMPORTANCE Induction of HIV Env antibodies at sufficient levels with optimal Fc effector functions for durable protection remains a challenge. Efficient T cell help may be essential to induce such a desirable antibody response. Here, we provide proof of concept that T helper cells induced by a licensed vaccine can be harnessed to provide help for HIV Env-specific B cells and to modulate the Env-specific IgG subtype response.
Ashraf A. Tabll, Rehab I. Moustafa, Yasmine S. El Abd, Noha G. Bader El Din, Reem El-Shenawy, Hassan Yousef, Manal Hussein, Reham M. Dawood, Moataza H. Omran, and Mostafa K. El-Awady Informa UK Limited
We characterized viral neutralization by a murine monoclonal antibody (mAb315) developed against conserved E1 specific epitope aa 315–323 at pre- and post-binding steps of infection into Huh7 cells. Detection of native virus in infected Huh7 cells by mAb315 were demonstrated by immunostaining. Inhibitions of viral entry by three different concentrations of mAb315 were measured by intracellular amplification of HCV RNA post infection. HCV RNA positive sera from 24 patients were used to infect Huh7 cell line in absence or presence of mouse monoclonal antibody produced in Balb/c mice or culture supernatant of mouse hybrid cells. Monoclonal Ab mAb315 could detect synthetic peptide p315 adsorbed on peripheral human lymphocytes by flow cytometry and showed high immuno reactivity to E1 viral antigen in infected Huh7 cells by immunostaining. Antibody-mediated neutralization assays demonstrated the ability of mAb315 to block HCV binding/entry to target cells at 0.73 mg/mL ascitic fluid or 250 µg/mL culture supernatant of mouse hybrid cells. Sixteen of 24 infected sera could infect Huh7 cells (67%). Binding/entry of HCV was completely blocked by mAb315 in 11/16 cases (69%). These findings suggest that mAb315 can induce HCV neutralization in vitro, which makes it a candidate for developing HCV therapeutic antibodies
Mostafa K. El-Awady, Ashraf A. Tabll, Hassan Yousif, Yasmin El-Abd, Mohamed Reda, Samy B. Khalil, Abdel Rahman El-Zayadi, Maysa H. Shaker, and Noha G. Bader El Din Elsevier BV
Mostafa K El-Awady, Ashraf A Tabll, Yasmine S El-Abd, Hassan Yousif, Mohsen Hegab, Mohamed Reda, Reem El Shenawy, Rehab I Moustafa, Nabila Degheidy, and Noha El Din Springer Science and Business Media LLC